tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

REGN Stock Latest News

Regeneron price target raised to $720 from $710 at BofA
The FlyRegeneron price target raised to $720 from $710 at BofA
4d ago
REGN
RBC sees buying opportunity following Regeneron’s ‘overdone DOJ downside’
PremiumThe Fly
RBC sees buying opportunity following Regeneron’s ‘overdone DOJ downside’
5d ago
REGN
Regeneron (NASDAQ:REGN) Accused of Manipulating Pricing
PremiumMarket News
Regeneron (NASDAQ:REGN) Accused of Manipulating Pricing
5d ago
REGN
DOJ files false claims act complaint against Regeneron over drug pricing
PremiumThe Fly
DOJ files false claims act complaint against Regeneron over drug pricing
6d ago
REGN
Regeneron presents pivotal data from Phase 1/2 LINKER-MM1 trial of linvoseltamab
PremiumThe Fly
Regeneron presents pivotal data from Phase 1/2 LINKER-MM1 trial of linvoseltamab
9d ago
REGN
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
PremiumPress ReleasesLinvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
9d ago
REGN
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
PremiumStock Analysis & Ideas
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
13d ago
LLY
BHVN
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
PremiumPress Releases
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
15d ago
REGN
Regeneron Provides Update on Biologics License Application for Odronextamab
PremiumPress Releases
Regeneron Provides Update on Biologics License Application for Odronextamab
22d ago
REGN
Regeneron receives CRL from FDA on odronextamab BLA
PremiumThe Fly
Regeneron receives CRL from FDA on odronextamab BLA
22d ago
REGN
Regeneron price target raised to $1,115 from $1,104 at Morgan Stanley
PremiumThe Fly
Regeneron price target raised to $1,115 from $1,104 at Morgan Stanley
1M ago
REGN
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
PremiumPress Releases
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
1M ago
REGN
Oracle, Dollar General upgraded: Wall Street’s top analyst calls
PremiumThe FlyOracle, Dollar General upgraded: Wall Street’s top analyst calls
1M ago
AM
DG
Regeneron initiated with an Outperform at Bernstein
PremiumThe Fly
Regeneron initiated with an Outperform at Bernstein
1M ago
REGN
Regeneron says FDA has extended approval of Praluent
PremiumThe Fly
Regeneron says FDA has extended approval of Praluent
1M ago
REGN
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
PremiumPress Releases
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
1M ago
REGN
Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint
PremiumThe Fly
Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint
1M ago
REGN
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
PremiumPress Releases
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
1M ago
REGN
2seventy bio: Close of asset sale to Regeneron seen in 1H24
PremiumThe Fly
2seventy bio: Close of asset sale to Regeneron seen in 1H24
1M ago
REGN
TSVT
Regeneron price target raised to $1,184 from $1,096 at RBC Capital
PremiumThe FlyRegeneron price target raised to $1,184 from $1,096 at RBC Capital
2M ago
REGN
Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
PremiumThe Fly
Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
2M ago
SNY
REGN
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
PremiumPress Releases
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
2M ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >